Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
07/19/2022 -- Results Q2 2022 -- -- --
07/19/2022 -- Earnings Call Q2 2022 -- -- --
04/26/2022 -- Results Q1 2022 -- -- --
04/26/2022 08:00 EST Earnings Call Q1 2022 -- -- --
02/02/2022 -- Results Q4 2021 -- -- --
02/02/2022 -- Earnings Call Q4 2021 -- -- --
10/26/2021 -- Results Q3 2021 -- -- --
10/26/2021 -- Earnings Call Q3 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 07/19/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade
 
4.00
2.00
1.00
 
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
No data available
Last Report Date 04/26/2022
Beat/Miss Upgrade
Return Since -7.32%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
URL https://www.novartis.com
Investor Relations URL https://www.novartis.com/investors
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Jul. 19, 2022
Last Earnings Release Apr. 26, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Mar. 08, 2022

Dividends

Dividend Per Share (TTM) 3.358
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 3.000
Yield to Sector 2.280
Yield to Industry 1.180
Last Dividend Amt. 3.348
Dividend Frequency Annually
Last Ex-Dividend Date Mar. 08, 2022
Yield (TTM) 3.99%
Forward Yield 3.98%
Payout Ratio 31.04%
Cash Payout Ratio 64.61%
Consistent Payer (5Y) No
Consistent Growth (5Y) Yes

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-6.82%
-13.51%
20.92%
2.80%
12.74%
2.74%
-3.23%
-0.04%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.31%
--
--
-1.39%
-26.17%
-9.84%
-39.32%
-4.26%
-34.75%
--
--
15.89%
21.68%
113.2%
151.4%
-50.51%
-11.64%
--
--
--
29.71%
-69.83%
-45.55%
-4.33%
-5.03%
--
--
--
--
--
--
-53.06%
-82.51%
As of June 24, 2022.

Profile

Edit
Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
URL https://www.novartis.com
Investor Relations URL https://www.novartis.com/investors
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Jul. 19, 2022
Last Earnings Release Apr. 26, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Mar. 08, 2022

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
DISCX 144.21M CHF 2.42%
TIEHX 128.90M CHF 2.30%
JIGIX 165.82M CHF 1.59%
HTY 954653.0 CHF 1.45%
HEQ 1.761M CHF 1.34%
FSPSX 466.48M CHF 1.25%
TCIHX 220.14M CHF 1.25%
ETW 12.62M CHF 1.23%
FSGEX 244.55M CHF 0.80%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership